Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

VBI Vaccines, Inc. - Ordinary Shares (NQ: VBIV )

0.0653 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VBI Vaccines, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
VBI Vaccines Reports Third Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
From VBI Vaccines Inc.
Via Business Wire
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Second Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
Over $27M Bet On This Consumer Cyclical Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
7 Biotech Stocks to Sell in July
Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July. 
Via InvestorPlace
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
Nasdaq Drops Over 100 Points; Genius Sports Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. The Dow traded down 1.09% to 33,913.56 while the NASDAQ fell 0.96% to 13,659.77. The... 
Via Benzinga
Crude Oil Moves Lower; ISM Services PMI Surges In June
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Thursday. The Dow traded down 1.38% to 33,814.23 while the NASDAQ fell 1.37% to 13,602.19. The S&P 500,... 
Via Benzinga
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. 
Via Benzinga
Why Is Kazia Therapeutics (KZIA) Stock Moving Today?
Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program. 
Via InvestorPlace
Dow Tumbles Over 300 Points; US Jobless Claims Increase More Than Projected
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. Following the market opening Thursday, the Dow traded down 0.96% to 33,958.13 while the NASDAQ fell 1.06%... 
Via Benzinga
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?
Nymox Pharmaceutical (NYMX) stock is falling on Thursday after the company told investors its shares will be delisted tomorrow. 
Via InvestorPlace
Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
VBI Vaccines (VBIV) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. 
Via InvestorPlace
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
From VBI Vaccines Inc.
Via Business Wire
Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company. 
Via Benzinga
VBI Vaccines, Brii Biosciences Expand Hepatitis B Immunotherapy Pact
VBI Vaccines Inc (NASDAQ: VBIV) expanded its hepatitis B (HBV) partnership with Brii Biosciences to work on  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! 
Via InvestorPlace
Levi Strauss, VBI Vaccines And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.